DCRI Statistician Advocates for Open Science During COVID-19
A DCRI expert in open science and data sharing recently contributed to a letter to the editor voicing the importance of open science in COVID-19 research.
The letter, published recently in Therapeutic Innovation & Regulatory Science, was authored by DCRI’s Frank Rockhold, PhD, along with two other authors who were both funded by The Gates Foundation. The letter reviewed work already being undertaken by the International COVID-19 Data Research Alliance (ICODA) and provided recommendations for upcoming clinical trials for COVID-19 therapeutics and vaccines.
New Study Analyzes Secondary COVID-19 Transmission for In-Person Schooling
The rate of transmission within schools was found to be much lower than the rate of community spread of the disease.
Global Digital Health Expert, Eric Perakslis, PhD, to Join Duke Clinical Research Institute as Chief Science & Digital Officer
Perakslis will provide strategic vision and oversight of DCRI’s digital research initiatives and technology affairs to advance the academic institute’s clinical research portfolio.
DCRI, Verily, and HERO Registry to Support Long-Term Safety Study of COVID-19 Vaccine
The Duke Clinical Research Institute (DCRI) and Verily are utilizing the HERO Registry and community to launch a study to gain long-term insights about the COVID-19 vaccine developed by Pfizer and BioNTech, including real-world safety data. This study, which is funded by Pfizer, will follow vaccinated healthcare workers for two years to assess their experiences after receiving the vaccine.
Novel Blueprint Leverages Behavioral Economics to Inform Clinical Practice
Data from electronic health record (EHR) systems—including on prescribing patterns—are often not available to clinicians in an aggregated or easily digestible format.
Survey Designed by DCRI Gains Insight into COVID-19 Preferences
DCRI population health scientists conducted a discrete choice experiment to improve understanding of how people weigh risks associated with COVID-19. A partisan split in reaction to COVID-19 has been widely publicized in the media—but new research from DCRI population health scientists suggests that it may not be that simple.
DCRI Faculty Members Recognized as ‘Pioneers’
The annual list, which examined papers published over the last decade, honors researchers who were in the top 1 percent of citations in their fields.
DCRI’s CEC Group Contributes to AHA Late-Breakers
Through new ways of working and collaborations across Duke, the DCRI’s Clinical Events Classification group is continuously improving on its processes.
AHA 2020: RIVER Shows Rivaroxaban Safe for Patients with Bioprosthetic Valves
The study, which is the only randomized trial testing rixaroxaban in this patient population, builds on previous evidence established by the DCRI-led ROCKET-AF and ARISTOTLE studies.
AHA 2020: GALACTIC-HF Finds Investigational Therapy to be Effective
Patients assigned to the treatment, omecamtiv mecarbil, experienced a statistically significant difference in a composite endpoint of time to cardiovascular death or time to first heart failure event.